Replies to post #153110 on Biotech Values

[DonShimoda]

Is the HCC indication enough to make you a buyer?

The short answer is yes. ARQL's tivantinib has shown to be active in multiple indications. The 2nd-line, HCC Phase 2 results are compelling. Given that it was a randomized, double-blind trial, i'm hoping the results can be replicated in the phase 3, however, it is going to be a long wait with few new catalysts (mCRC) to drive the stock in the near-term.